107 related articles for article (PubMed ID: 2433360)
21. Oncogene from human EJ bladder carcinoma is located on the short arm of chromosome 11.
de Martinville B; Giacalone J; Shih C; Weinberg RA; Francke U
Science; 1983 Feb; 219(4584):498-501. PubMed ID: 6297001
[TBL] [Abstract][Full Text] [Related]
22. Effects of interferons alpha,beta,gamma alone or in combination on the phenotype of human colon carcinoma cells.
Brouty-Boyé D; Maunoury MT; Lowy R
Anticancer Res; 1988; 8(1):197-203. PubMed ID: 2451894
[TBL] [Abstract][Full Text] [Related]
23. Suppression of tumorigenicity in human cell hybrids derived from cell lines expressing different activated ras oncogenes.
Geiser AG; Anderson MJ; Stanbridge EJ
Cancer Res; 1989 Mar; 49(6):1572-7. PubMed ID: 2647289
[TBL] [Abstract][Full Text] [Related]
24. Analysis of metastatic competence of mouse bladder carcinoma cells after transfection with activated Ha-ras or N-ras oncogenes.
Pohl J; Radler-Pohl A; Franks LM; Schirrmacher V
J Cancer Res Clin Oncol; 1988; 114(4):373-9. PubMed ID: 3410877
[TBL] [Abstract][Full Text] [Related]
25. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene.
Parada LF; Tabin CJ; Shih C; Weinberg RA
Nature; 1982 Jun; 297(5866):474-8. PubMed ID: 6283357
[TBL] [Abstract][Full Text] [Related]
26. Activated Ki-ras genes in bladder epithelial cell lines transformed by treatment of primary mouse bladder explant cultures with 7,12-dimethylbenz[a]anthracene.
Brookes P; Cooper CS; Ellis MV; Warren W; Gardner E; Summerhayes IC
Mol Carcinog; 1988; 1(2):82-8. PubMed ID: 3151261
[TBL] [Abstract][Full Text] [Related]
27. Regulation of the antigenic phenotype of human melanoma cells by recombinant interferons.
Giacomini P; Gambari R; Barbieri R; Nisticò P; Tecce R; Pestka S; Gustafsson K; Natali PG; Fisher PB
Anticancer Res; 1986; 6(5):877-84. PubMed ID: 2432832
[TBL] [Abstract][Full Text] [Related]
28. Interferons and bone. A comparison of the effects of interferon-alpha and interferon-gamma in cultures of human bone-derived cells and an osteosarcoma cell line.
Beresford JN; Taylor GT; Triffitt JT
Eur J Biochem; 1990 Oct; 193(2):589-97. PubMed ID: 2121483
[TBL] [Abstract][Full Text] [Related]
29. Integration and loss of a single v-Ki-ras gene affects tumorigenic potential of human osteosarcoma cells.
Carloni G; Venuat AM; Daya-Grosjean L; Nardeux P; Rhim JS; Azzarone B
FEBS Lett; 1988 Mar; 229(2):333-9. PubMed ID: 2831097
[TBL] [Abstract][Full Text] [Related]
30. Reversion by deletion of transforming oncogene following interferon-beta and retinoic acid treatment.
Friedman RM; Yeh A; Gutman P; Contente S; Kenyon K
J Interferon Cytokine Res; 1997 Oct; 17(10):647-51. PubMed ID: 9355967
[TBL] [Abstract][Full Text] [Related]
31. Characterization of a gastric tumor cell line defective in MHC class I inducibility by both alpha- and gamma-interferon.
Abril E; Mendez RE; García A; Serrano A; Cabrera T; Garrido F; Ruiz-Cabello F
Tissue Antigens; 1996 May; 47(5):391-8. PubMed ID: 8795139
[TBL] [Abstract][Full Text] [Related]
32. Ha-ras oncogenes are activated by somatic alterations in human urinary tract tumours.
Fujita J; Yoshida O; Yuasa Y; Rhim JS; Hatanaka M; Aaronson SA
Nature; 1984 May 31-Jun 6; 309(5967):464-6. PubMed ID: 6328318
[TBL] [Abstract][Full Text] [Related]
33. Malignant properties of sublines selected from a human bladder cancer cell line that contains an activated c-Ha-ras oncogene.
Kovnat A; Buick RN; Choo B; De Harven E; Kopelyan I; Trent JM; Tannock IF
Cancer Res; 1988 Sep; 48(17):4993-5000. PubMed ID: 3409229
[TBL] [Abstract][Full Text] [Related]
34. Cellular ras activity and tumor cell proliferation.
Stacey DW; DeGudicibus SR; Smith MR
Exp Cell Res; 1987 Jul; 171(1):232-42. PubMed ID: 3622632
[TBL] [Abstract][Full Text] [Related]
35. Expression of cellular oncogenes in human gastric carcinoma: c-myc, c-erb B2, and c-Ha-ras.
Kim YJ; Ghu HD; Kim DY; Kim HJ; Kim SK; Park CS
J Surg Oncol; 1993 Nov; 54(3):167-70. PubMed ID: 8412172
[TBL] [Abstract][Full Text] [Related]
36. Activating missense mutations in Ha-ras-1 genes in a malignant subset of bladder lesions induced by N-butyl-N-(4-hydroxybutyl)nitrosamine or N-[4-(5-nitro-2-furanyl)-2-thiazolyl]formamide.
Jones RF; Debiec-Rychter M; Zukowski K; Wang CY
Mol Carcinog; 1990; 3(6):393-402. PubMed ID: 2278634
[TBL] [Abstract][Full Text] [Related]
37. T24 human bladder carcinoma cells with activated Ha-ras protooncogene: nontumorigenic cells susceptible to malignant transformation with carcinogen.
Senger DR; Perruzzi CA; Ali IU
Proc Natl Acad Sci U S A; 1988 Jul; 85(14):5107-11. PubMed ID: 3293049
[TBL] [Abstract][Full Text] [Related]
38. Activated oncogenes in human tumors.
Suárez HG
Anticancer Res; 1989; 9(5):1331-43. PubMed ID: 2686533
[TBL] [Abstract][Full Text] [Related]
39. Reversal of the malignant phenotype by an anti-ras ribozyme.
Kashani-Sabet M; Funato T; Tone T; Jiao L; Wang W; Yoshida E; Kashfinn BI; Shitara T; Wu AM; Moreno JG
Antisense Res Dev; 1992; 2(1):3-15. PubMed ID: 1422085
[TBL] [Abstract][Full Text] [Related]
40. Antiproliferative activities of interferons against human bladder carcinoma cell lines in vitro.
Borden EC; Groveman DS; Nasu T; Reznikoff C; Bryan GT
J Urol; 1984 Oct; 132(4):800-3. PubMed ID: 6206246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
